Gufic Biosciences, 509079, GUFICBIO Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

2,219.06
23.15
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

2,261.23
0.04%
8.25

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

19.29
14.71
11.61

EBITDA CAGR (%)

10 Years
5 Years
3 Years

27.59
29.60
12.78

PAT CAGR (%)

10 Years
5 Years
3 Years

39.99
37.44
26.33

P:E (Median)

8 Years
5 Years
3 Years

35.69
32.84
26.43

P:BV (Average)

8 Years
5 Years
3 Years

8.31
8.31
8.31

EV:EBITDA (Average)

8 Years
5 Years
3 Years

17.19
18.11
15.67

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 22 Mar 21 Var% Dec 21 Dec 20 Var% Sep 21 Sep 20 Var% Jun 21 Jun 20 Var%
Net Sales 162.19 131.93 22.94% 172.06 166.56 3.30% 194.14 128.42 51.18% 250.76 60.80 312.43%
Expenses 130.67 108.18 20.79% 139.35 139.13 0.16% 158.31 99.01 59.89% 205.11 57.45 257.02%
EBITDA 31.52 23.75 32.72% 32.72 27.42 19.33% 35.83 29.40 21.87% 45.65 3.35 1,262.69%
EBIDTM 19.43% 18.00% 19.02% 16.46% 18.46% 22.90% 18.20% 5.51%
Other Income 0.04 0.66 -93.94% 1.53 0.03 5,000.00% 0.31 2.26 -86.28% 1.23 0.78 57.69%
Interest 1.06 2.87 -63.07% 1.03 3.78 -72.75% 1.55 3.60 -56.94% 1.21 3.38 -64.20%
Depreciation 4.33 4.48 -3.35% 4.48 3.22 39.13% 4.20 5.05 -16.83% 4.13 3.55 16.34%
PBT 26.18 17.05 53.55% 28.73 20.45 40.49% 30.39 23.01 32.07% 41.54 -2.80 -
Tax 5.91 4.18 41.39% 7.70 4.99 54.31% 7.05 5.68 24.12% 10.33 -1.36 -
PAT 20.27 12.87 57.50% 21.03 15.46 36.03% 23.34 17.33 34.68% 31.21 -1.43 -
PATM 12.49% 9.76% 12.22% 9.29% 12.02% 13.50% 12.45% -2.36%
EPS 2.09 1.33 57.14% 2.17 1.60 35.62% 2.41 1.79 34.64% 3.22 -0.15 -

Description Dec 21 Dec 20 Var% Sep 21 Sep 20 Var% Jun 21 Jun 20 Var% Mar 21 Mar 20 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Net Sales 779.15 487.70 378.84 350.77 305.58 245.52 202.20 151.55 123.01 100.14 83.57 Net Sales Growth 59.76% 28.74% 8.00% 14.79% 24.46% 21.42% 33.42% 23.20% 22.84% 19.83% Cost Of Goods Sold 411.96 226.12 156.47 161.37 128.58 107.42 90.84 73.47 55.61 46.05 40.87 Gross Profit 367.19 261.58 222.37 189.40 177.01 138.10 111.35 78.08 67.40 54.09 42.70 GP Margin 47.13% 53.64% 58.70% 54.00% 57.93% 56.25% 55.07% 51.52% 54.79% 54.01% 51.09% Total Expenditure 633.44 403.78 326.72 304.78 266.80 222.57 182.51 137.28 110.98 89.40 76.23 Power & Fuel Cost - 9.94 8.23 3.43 3.58 3.51 3.57 3.16 2.95 3.21 2.50 % Of Sales - 2.04% 2.17% 0.98% 1.17% 1.43% 1.77% 2.09% 2.40% 3.21% 2.99% Employee Cost - 66.22 58.59 46.85 44.62 41.03 31.95 19.23 12.25 5.45 4.37 % Of Sales - 13.58% 15.47% 13.36% 14.60% 16.71% 15.80% 12.69% 9.96% 5.44% 5.23% Manufacturing Exp. - 46.74 43.26 43.16 37.69 28.94 23.54 15.48 17.33 9.14 7.49 % Of Sales - 9.58% 11.42% 12.30% 12.33% 11.79% 11.64% 10.21% 14.09% 9.13% 8.96% General & Admin Exp. - 23.69 32.47 32.32 31.50 27.03 20.56 13.56 8.82 3.79 4.96 % Of Sales - 4.86% 8.57% 9.21% 10.31% 11.01% 10.17% 8.95% 7.17% 3.78% 5.94% Selling & Distn. Exp. - 17.87 17.35 11.36 13.26 9.11 8.19 8.78 12.41 19.92 15.85 % Of Sales - 3.66% 4.58% 3.24% 4.34% 3.71% 4.05% 5.79% 10.09% 19.89% 18.97% Miscellaneous Exp. - 13.20 10.36 6.29 7.57 5.53 3.85 3.61 1.61 1.84 15.85 % Of Sales - 2.71% 2.73% 1.79% 2.48% 2.25% 1.90% 2.38% 1.31% 1.84% 0.22% EBITDA 145.72 83.92 52.12 45.99 38.78 22.95 19.69 14.27 12.03 10.74 7.34 EBITDA Margin 18.70% 17.21% 13.76% 13.11% 12.69% 9.35% 9.74% 9.42% 9.78% 10.72% 8.78% Other Income 3.11 3.73 5.79 4.17 2.86 1.44 0.66 0.57 0.63 0.39 0.37 Interest 4.85 13.63 13.91 10.16 8.88 6.34 6.20 4.46 3.92 3.69 2.85 Depreciation 17.14 16.31 13.86 4.65 4.40 3.68 3.79 3.85 2.47 2.18 1.88 PBT 126.84 57.71 30.13 35.35 28.37 14.37 10.36 6.53 6.27 5.26 2.97 Tax 30.99 13.48 7.44 13.41 13.48 5.35 3.03 2.37 2.01 1.93 1.44 Tax Rate 24.43% 23.36% 24.69% 37.93% 44.99% 37.23% 29.25% 36.29% 32.06% 36.69% 48.48% PAT 95.85 44.23 22.69 21.94 16.48 9.02 7.32 4.16 4.26 3.33 1.53 PAT before Minority Interest 95.85 44.23 22.69 21.94 16.48 9.02 7.32 4.16 4.26 3.33 1.53 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 12.30% 9.07% 5.99% 6.25% 5.39% 3.67% 3.62% 2.74% 3.46% 3.33% 1.83% PAT Growth 116.71% 94.93% 3.42% 33.13% 82.71% 23.22% 75.96% -2.35% 27.93% 117.65% EPS 9.89 4.56 2.34 2.26 1.70 0.93 0.76 0.43 0.44 0.34 0.16

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Shareholder's Funds 173.44 129.32 75.35 54.14 37.33 33.96 27.10 26.21 22.39 19.51 Share Capital 9.69 9.69 7.78 7.78 7.74 7.74 7.74 7.74 7.74 7.74 Total Reserves 163.74 119.63 67.56 46.35 29.59 26.22 19.36 18.47 14.66 11.78 Non-Current Liabilities 54.96 37.79 17.16 12.54 9.16 14.56 16.58 24.63 23.53 8.75 Secured Loans 35.43 19.52 11.25 4.43 3.20 4.84 8.62 10.17 13.72 1.65 Unsecured Loans 0.00 0.03 0.06 3.89 3.42 2.82 2.88 4.71 4.72 2.67 Long Term Provisions 10.23 7.93 1.86 2.26 2.29 1.39 1.41 1.35 1.19 1.00 Current Liabilities 219.85 325.60 217.72 168.55 128.18 103.68 83.61 60.31 43.65 47.06 Trade Payables 113.03 117.07 77.81 75.98 43.74 52.62 49.53 31.80 20.14 22.22 Other Current Liabilities 28.16 22.99 16.28 17.24 20.75 14.10 13.01 11.28 7.74 6.42 Short Term Borrowings 16.32 93.10 84.69 69.17 46.97 32.28 17.90 14.77 13.74 15.32 Short Term Provisions 62.33 92.44 38.95 6.16 16.73 4.67 3.16 2.47 2.04 3.10 Total Liabilities 448.25 492.71 310.23 235.23 174.67 152.20 127.29 111.15 89.57 75.32 Net Block 99.97 82.58 24.45 22.85 21.96 22.15 25.11 30.23 26.83 17.71 Gross Block 148.64 114.98 37.19 31.00 25.65 51.31 50.81 48.46 42.59 31.60 Accumulated Depreciation 48.67 32.40 12.74 8.15 3.68 29.17 25.71 18.23 15.76 13.89 Non Current Assets 131.48 133.58 46.34 37.02 31.42 32.69 35.81 41.84 39.36 24.33 Capital Work in Progress 13.40 30.61 9.63 2.05 0.04 0.00 0.00 0.00 2.98 1.07 Non Current Investment 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 Long Term Loans & Adv. 17.12 18.54 10.16 8.73 7.60 9.01 9.17 11.32 7.34 5.49 Other Non Current Assets 0.98 1.84 2.09 3.38 1.82 1.52 1.52 0.28 2.20 0.05 Current Assets 316.77 359.13 263.89 198.20 143.25 119.51 91.48 69.30 50.22 50.99 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 94.40 122.46 94.28 94.20 63.02 50.26 36.80 26.12 20.00 16.91 Sundry Debtors 124.50 106.97 103.18 80.80 52.12 56.23 33.38 28.21 20.01 22.57 Cash & Bank 13.18 16.37 7.59 7.50 5.64 6.16 6.21 2.54 1.28 0.96 Other Current Assets 84.69 0.84 1.10 0.38 22.47 6.86 15.08 12.44 8.93 10.55 Short Term Loans & Adv. 84.00 112.48 57.74 15.33 21.38 6.10 12.45 9.60 7.19 10.22 Net Current Assets 96.92 33.53 46.17 29.66 15.07 15.84 7.87 8.99 6.57 3.93 Total Assets 448.25 492.71 310.23 235.22 174.67 152.20 127.29 111.14 89.58 75.32

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Cash From Operating Activity 89.06 47.10 5.21 -4.82 -4.13 -4.32 11.15 10.87 5.26 5.16 PBT 57.71 30.13 35.35 29.95 14.37 11.19 6.53 6.27 5.26 2.97 Adjustment 30.79 24.63 13.35 12.07 9.75 8.84 8.19 6.27 5.95 4.86 Changes in Working Capital 9.97 2.48 -33.52 -30.40 -23.70 -21.31 -1.60 -0.19 -4.42 -1.87 Cash after chg. in Working capital 98.47 57.24 15.18 11.63 0.42 -1.28 13.12 12.36 6.79 5.97 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -9.40 -10.14 -9.98 -16.44 -4.55 -2.65 -1.96 -1.49 -1.54 -0.80 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 -0.38 0.00 0.00 0.00 0.00 Cash From Investing Activity -8.51 -42.53 -12.99 -8.84 -4.69 -0.51 -2.39 -2.78 -13.26 -3.33 Net Fixed Assets -16.45 -98.77 -13.77 -7.36 25.62 -0.50 -2.35 -2.89 -12.90 -3.26 Net Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Others 7.94 56.24 0.78 -1.48 -30.31 -0.01 -0.04 0.11 -0.36 -0.07 Cash from Financing Activity -78.62 -4.21 7.71 14.40 7.41 4.78 -5.09 -6.82 8.32 -1.82 Net Cash Inflow / Outflow 1.94 0.37 -0.08 0.75 -1.41 -0.05 3.67 1.26 0.32 0.02 Opening Cash & Equivalents 4.26 3.90 3.74 2.99 4.28 6.21 2.54 1.28 0.96 0.95 Closing Cash & Equivalent 6.20 4.26 3.66 3.74 2.87 6.16 6.21 2.54 1.28 0.96

Financial Ratios

Standalone

Description Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Book Value (Rs.) 17.89 13.34 9.68 6.96 4.83 4.39 3.50 3.39 2.90 2.52 ROA 9.40% 5.65% 8.04% 8.04% 5.52% 5.24% 3.49% 4.25% 4.04% 2.20% ROE 29.22% 22.17% 33.89% 36.03% 25.31% 23.99% 15.60% 17.55% 15.89% 8.05% ROCE 30.05% 21.01% 29.65% 34.10% 24.26% 24.24% 18.38% 17.45% 18.44% 15.02% Fixed Asset Turnover 3.71 5.14 10.57 11.21 6.77 4.19 3.22 2.86 2.85 2.83 Receivable days 86.30 97.98 93.16 76.39 75.93 76.38 70.29 67.55 73.52 84.97 Inventory Days 80.86 101.05 95.44 90.36 79.39 74.21 71.80 64.60 63.71 62.71 Payable days 185.71 115.05 115.32 80.93 87.99 110.87 119.47 95.34 87.64 91.90 Cash Conversion Cycle -18.55 83.98 73.27 85.82 67.32 39.73 22.62 36.81 49.59 55.78 Total Debt/Equity 0.32 0.90 1.30 1.47 1.52 1.26 1.21 1.27 1.55 1.05 Interest Cover 5.23 3.17 4.48 4.37 3.27 2.67 2.46 2.60 2.43 2.04

Top Investors:

jagdish n master

sbi healthcare opportunities fund

girish gulati huf

llp

iepf

Annual Reports:

News Update:

Gufic Biosciences - Quarterly Results
20th May 2022, 19:16 PM

Read More
Gufic Biosciences to manufacture, sell, distribute Isavuconazonium Sulfate API & finished formulation Isavuconazole
11th Apr 2022, 17:43 PM

Isavuconazole for Injection 200 mg/vial is indicated for the treatment of patients having 18 years of age and older for the treatment of Invasive Aspergillosis and Invasive Mucormycosis
Read More
Gufic Biosciences gets DCGI nod for Thymosin Alpha-1
5th Apr 2022, 16:48 PM

Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 Clinical trial in adult patients with moderate-to-severe Covid-19
Read More
Gufic Biosciences incorporates wholly owned subsidiary company
17th Mar 2022, 11:20 AM

Gufic UK is incorporated with the object to expand its pharmaceutical business in United Kingdom
Read More
Gufic Biosciences enters into research and collaboration agreement with Selvax
10th Mar 2022, 09:52 AM

Selvax considers Gufic as an ideal collaboration partner on account of Gufic's long track record of innovation and new drug development
Read More

Gufic Biosciences Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 509079 | NSE: GUFICBIO

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update:

Gufic Biosciences Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 509079 | NSE: GUFICBIO

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update: